Patrick Forde, MBBCh, shares insights on perioperative immunotherapy in the CheckMate-77T study presented at ESMO 2023. This is a video synopsis/summary of a Post Conference Perspectives involving ...
Clinical research presented at the European Society for Medical Oncology Congress 2024 highlights the significant survival benefits of perioperative and neoadjuvant immunotherapy with nivolumab and ...
(Barcelona, Spain September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — An analysis from the Phase 3 CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of ...
Results from the Phase III CheckMate -77T trial show that Opdivo (nivolumab) plus chemotherapy followed by surgery and adjuvant Opdivo produced statistically significant and clinically meaningful ...
It’s not a proper market showdown without all the players. And in the perioperative treatment of early-stage, non-small cell lung cancer with a PD-1/L1 inhibitor, the field is quickly taking shape.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results